ibuzatrelvir + remdesivir

This combination therapy consists of **ibuzatrelvir**, an orally bioavailable SARS-CoV-2 main protease (Mpro, also known as 3CLpro) inhibitor, and **remdesivir**, a nucleotide analog prodrug that inhibits the viral RNA-dependent RNA polymerase. **Ibuzatrelvir** is designed to block viral replication by targeting and binding reversibly (via a nitrile warhead) to the active site of the coronavirus main protease, hindering cleavage of viral polyproteins essential for virus maturation[5]. **Remdesivir** acts by mimicking adenosine and, after intracellular activation, is incorporated into nascent viral RNA by the viral polymerase, leading to delayed chain termination and disruption of RNA synthesis[2][4][6]. This combination is being investigated for enhanced efficacy in the treatment of **COVID-19**, particularly in immunocompromised adults[3]. **Ibuzatrelvir** was developed by Pfizer and is in phase 3 clinical trials, while **remdesivir** is developed and manufactured by Gilead Sciences and is approved for COVID-19 treatment. The combination leverages complementary antiviral mechanisms to inhibit SARS-CoV-2 at different steps in its replication cycle.